Barclays
UNCY icon

Barclays’s Unicycive Therapeutics UNCY Stock Holding History

Barclays’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$329K Buy
50,000
+49,920
+62,400% +$327K ﹤0.01% 3429
2025
Q4 		$462 Hold
80
– – ﹤0.01% 5099
2025
Q3 		$349 Hold
80
– – ﹤0.01% 5219
2025
Q2 		$382 Buy
+80
New +$495 ﹤0.01% 5085

Other funds holding UNCY

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's UNCY Position: Q1 2026 in Review

Barclays increased its Unicycive Therapeutics (UNCY) stake by 62,400% in Q1 2026, buying an estimated $327K and bringing the position to 50,000 shares worth $329K. The position accounts for ﹤0.01% of the portfolio, ranked #3429.

Barclays first reported a position in UNCY in Q2 2025 and has held it in 4 quarters since. 51 funds tracked by Wall St. Rank hold UNCY as of Q1 2026.

  • Barclays held 50,000 shares of Unicycive Therapeutics worth $329K as of Q1 2026.
  • Barclays bought 49,920 Unicycive Therapeutics shares in Q1 2026, an estimated $327K.
  • Unicycive Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3429 holding.
  • Barclays first reported a position in Unicycive Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 51 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.